vs
QUALYS, INC.（QLYS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是QUALYS, INC.的1.2倍（$207.3M vs $175.3M），QUALYS, INC.净利率更高（30.3% vs -62.0%，领先92.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.1%），QUALYS, INC.自由现金流更多（$74.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.6%）
Qualys是总部位于美国加利福尼亚州福斯特城的科技企业，专注于云安全、合规管理及相关服务，为客户提供覆盖云环境的安全防护与合规解决方案，助力企业应对各类网络安全风险，满足不同行业的合规运营需求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
QLYS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $175.3M | $207.3M |
| 净利润 | $53.1M | $-128.6M |
| 毛利率 | 83.4% | — |
| 营业利润率 | 33.6% | -54.7% |
| 净利率 | 30.3% | -62.0% |
| 营收同比 | 10.1% | 25.9% |
| 净利润同比 | 20.9% | 3.5% |
| 每股收益（稀释后） | $1.47 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $175.3M | $207.3M | ||
| Q3 25 | $169.9M | $159.9M | ||
| Q2 25 | $164.1M | $166.5M | ||
| Q1 25 | $159.9M | $139.3M | ||
| Q4 24 | $159.2M | $164.6M | ||
| Q3 24 | $153.9M | $139.5M | ||
| Q2 24 | $148.7M | $147.0M | ||
| Q1 24 | $145.8M | $108.8M |
| Q4 25 | $53.1M | $-128.6M | ||
| Q3 25 | $50.3M | $-180.4M | ||
| Q2 25 | $47.3M | $-115.0M | ||
| Q1 25 | $47.5M | $-151.1M | ||
| Q4 24 | $44.0M | $-133.2M | ||
| Q3 24 | $46.2M | $-133.5M | ||
| Q2 24 | $43.8M | $-131.6M | ||
| Q1 24 | $39.7M | $-170.7M |
| Q4 25 | 83.4% | — | ||
| Q3 25 | 83.6% | — | ||
| Q2 25 | 82.4% | — | ||
| Q1 25 | 81.9% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 81.3% | — | ||
| Q2 24 | 82.2% | — | ||
| Q1 24 | 81.3% | — |
| Q4 25 | 33.6% | -54.7% | ||
| Q3 25 | 35.3% | -106.9% | ||
| Q2 25 | 31.3% | -64.8% | ||
| Q1 25 | 32.4% | -102.6% | ||
| Q4 24 | 31.0% | -74.3% | ||
| Q3 24 | 29.2% | -94.6% | ||
| Q2 24 | 32.3% | -79.1% | ||
| Q1 24 | 30.7% | -151.9% |
| Q4 25 | 30.3% | -62.0% | ||
| Q3 25 | 29.6% | -112.8% | ||
| Q2 25 | 28.8% | -69.0% | ||
| Q1 25 | 29.7% | -108.5% | ||
| Q4 24 | 27.6% | -80.9% | ||
| Q3 24 | 30.0% | -95.7% | ||
| Q2 24 | 29.4% | -89.5% | ||
| Q1 24 | 27.2% | -156.8% |
| Q4 25 | $1.47 | $-1.28 | ||
| Q3 25 | $1.39 | $-1.81 | ||
| Q2 25 | $1.29 | $-1.17 | ||
| Q1 25 | $1.29 | $-1.57 | ||
| Q4 24 | $1.19 | $-1.34 | ||
| Q3 24 | $1.24 | $-1.40 | ||
| Q2 24 | $1.17 | $-1.52 | ||
| Q1 24 | $1.05 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $250.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $561.2M | $-80.0M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $250.3M | $421.0M | ||
| Q3 25 | $225.3M | $202.5M | ||
| Q2 25 | $194.0M | $176.3M | ||
| Q1 25 | $290.7M | $127.1M | ||
| Q4 24 | $232.2M | $174.0M | ||
| Q3 24 | $235.4M | $150.6M | ||
| Q2 24 | $281.2M | $480.7M | ||
| Q1 24 | $273.8M | $112.3M |
| Q4 25 | $561.2M | $-80.0M | ||
| Q3 25 | $529.4M | $9.2M | ||
| Q2 25 | $508.2M | $151.3M | ||
| Q1 25 | $498.0M | $144.2M | ||
| Q4 24 | $477.1M | $255.0M | ||
| Q3 24 | $449.6M | $346.8M | ||
| Q2 24 | $427.8M | $432.4M | ||
| Q1 24 | $404.2M | $140.3M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $999.5M | $1.3B | ||
| Q1 25 | $996.5M | $1.3B | ||
| Q4 24 | $973.5M | $1.5B | ||
| Q3 24 | $908.3M | $1.5B | ||
| Q2 24 | $876.6M | $1.6B | ||
| Q1 24 | $861.8M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $74.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 42.8% | -48.6% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.42× | — |
| 过去12个月自由现金流最近4个季度 | $304.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $75.7M | $-99.8M | ||
| Q3 25 | $90.4M | $-91.4M | ||
| Q2 25 | $33.8M | $-108.3M | ||
| Q1 25 | $109.6M | $-166.5M | ||
| Q4 24 | $47.7M | $-79.3M | ||
| Q3 24 | $61.0M | $-67.0M | ||
| Q2 24 | $49.8M | $-77.0M | ||
| Q1 24 | $85.5M | $-190.7M |
| Q4 25 | $74.9M | $-100.8M | ||
| Q3 25 | $89.5M | $-92.7M | ||
| Q2 25 | $32.4M | $-110.7M | ||
| Q1 25 | $107.5M | $-167.8M | ||
| Q4 24 | $41.9M | $-79.5M | ||
| Q3 24 | $57.6M | $-68.6M | ||
| Q2 24 | $48.8M | $-79.0M | ||
| Q1 24 | $83.5M | $-193.9M |
| Q4 25 | 42.8% | -48.6% | ||
| Q3 25 | 52.7% | -58.0% | ||
| Q2 25 | 19.8% | -66.5% | ||
| Q1 25 | 67.3% | -120.5% | ||
| Q4 24 | 26.3% | -48.3% | ||
| Q3 24 | 37.4% | -49.2% | ||
| Q2 24 | 32.8% | -53.7% | ||
| Q1 24 | 57.2% | -178.2% |
| Q4 25 | 0.4% | 0.5% | ||
| Q3 25 | 0.5% | 0.8% | ||
| Q2 25 | 0.8% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 3.7% | 0.1% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 1.4% | 3.0% |
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 2.31× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
